cancertherapyadv.bsky.social
CancerTherapyAdvisor.com is a resource offering oncology health care professionals practical information about the changing clinical landscape.
👤 Joined on 03 December 2024
Followers
Following
Total Posts
@cancertherapyadv.bsky.socialmRNA vaccines continue to show major promise. In a small Phase 1 trial led by Dr. Balachandran, some patients with pancreatic cancer (one of the deadliest cancers) reached 6-year survival. This is why sustained investment in science & research matters. tinyurl.com/f4n4anhk
Show PostWhat workouts help during and after breast cancer? After breast cancer or after menopause, women need to exercise using strength and resistance training to maintain muscle mass and health. Learn expert tips on exercise, recovery, and feeling your best. https://bit.ly/49E3pyH
Show PostMen are twice as likely as women to have stage III #multiplemyeloma at diagnosis and appear to have a greater #tumor burden than women. Published in @cancertherapyadv.bsky.social https://bit.ly/45Quhcg
Show PostReducing the induction daunorubicin dose among pediatric patients with low-risk B-cell acute #lymphoblasticLeukemia appears to reduce toxicity without compromising efficacy. Published in @ascopost.bsky.social and @hematologyadvisor.bsky.social. https://bit.ly/4cmwfVQ #leusm #ALL
Show PostExcellent presentation on Resistance to Treatments Targeting the RAS/RAF/MEK Pathways by Sandra Misale, PhD, Johns Hopkins at #GI26 Genetic, nongenetic mechanisms, reshaping TME. Different patterns of resistance seen between inhibitors of specific KRAS alleles vs pan-RAS inhibitors.
Show Post